Oviductal glycoprotein (OVGP1, MUC9): A differentiation-based mucin present in serum of women with ovarian cancer

International Journal of Gynecological Cancer

Volumn 20, Issue 1, 2010, Pages 16-22

  Maines Bandiera, Sarah ^a   Woo, Michelle M M ^a   Borugian, Marilyn ^a   Molday, Laurie L ^a   Hii, Theresa ^a   Gilks, Blake ^a   Leung, Peter C K ^a   Molday, Robert S ^a   Auersperg, Nelly ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Differentiation; MUC9; Ovarian cancer; OVGP1; Oviductal glycoprotein; Serum marker

Indexed keywords

CA 125 ANTIGEN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7E10; MUCIN; OVIDUCTAL GLYCOPROTEIN 1; OVIDUCTAL GLYCOPROTEIN MUC9; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENDOMETRIOID OVARIAN CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARIAN CLEAR CELL CARCINOMA; OVARIAN MUCINOUS CARCINOMA; OVARIAN SEROUS CARCINOMA; OVARY CARCINOMA; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CYSTADENOCARCINOMA, SEROUS; FEMALE; GLYCOPROTEINS; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 74249118783     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181bcc96d     Document Type: Article

References (25)

1. Badgwell D, Bast RC Jr Early detection of ovarian cancer Dis Markers 2007;23:397-410.
2. Marchini S, Mariani P, Chiorino G, et al Analysis of gene expression in early-stage ovarian cancer Clinical Cancer Res 2008;14:7850-7860.
3. Le Page C, Ouellet V, Madore J, et al From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer Int J Cancer 2006;118:1750-1758.
4. Zhang Z, Yu Y, Xu F, et al Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer Gynecol Oncol 2007;107:526-531.
5. Menon U, Gentry-Maharaj A, Rachel Hallett R, et al Sensitivity and specificity of multimodal and ultrasoundscreening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Lancet Oncol 2009;10:327-340.
6. Moore RG, McMeekin DS, Brown AK, et al A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 2009;112:40-46.
7. Nolen B, Marrangoni A, Velikokhatnaya L, et al A serum based analysis of ovarian epithelial tumorigenesis Gynecol Oncol 2009;112:47-54.
8. Singer G, Kurman RJ, Chang HW, et al Diverse tumorigenic pathways in ovarian serous carcinoma Am J Pathol 2002; 160:1223-1228.
9. Köbel M, Kalloger SE, Boyd N, et al Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 2008;5:e232.
10. Kurman RJ, Shih M Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 2008;27:151-160.
11. Obata K, Morland SJ, Watson RH, et al Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors Cancer Res 1998;58:2095-2097.
12. Wen WH, Reles A, Runnebaum IB, et al p53 mutations and expression in ovarian cancers: correlation with overall survival Int J Gynecol Pathol 1999;18:29-41.
13. Schmidt A, Mavrogianis PA, O'Day-Bowman MB, et al Characterization of antibodies generated against a conserved portion of oviductal glycoprotein (OGP) and endogenous hamster OGP and their ability to decrease sperm binding to the zona pellucida in vitro Am J Reprod Immunol 1997; 38:377-383.
14. Verhage HG, Mavrogianis PA, O'Day-Bowman MB, et al Characteristics of an oviductal glycoprotein and its potential role in the fertilization process Biol Reprod 1998;58: 1098-1101.
15. Buhl WC Characterization and biological roles of oviduct-specific, oestrogen-dependent glycoprotein Reproduction 2002;123:355-362.
16. Singh AP, Senapati S, Ponnusamy MP Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer Lancet Oncol 2008;9:1076-1085.
17. Chauhan SC, Singh AP, Ruiz F, et al Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) Mod Pathol 2006;19:1386-1394.
18. Kadam KM, D'Souza SJ, Natraj U Identification of cellular isoform of oviduct-specific glycoprotein: role in oviduct tissue remodeling? Cell Tissue Res 2007;330:545-556.
19. Woo MM, Gilks CB, Verhage HG, et al Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts Gynecol Oncol 2004;93:315-319
20. Woo MM, Alkushi A, Verhage HG, et al Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer Clin Cancer Res 2004;10:7958-7964.
21. Hodges RS, Heaton RJ, Parker JM, et al Antigen-antibody interactions Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxy terminus of rhodopsin J Biol Chem 1988;263:11768-11775.
22. Tan DS, Kyle SJ Ovarian clear cell adenocarcinoma: a continuing enigma J Clin Pathol 2007;60:355-360.
23. Boman F, Buisine MP, Wacrenier A, et al Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study J Pathol 2001;193: 339-344.
24. Jordan SJ, Green AC, Whiteman DC, et al Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiologic evidence of a neoplastic continuum? Gynecol Oncol 2007;107:223-227.
25. Farley J, Ozbun LL, Birrer MJ Genomic analysis of epithelial ovarian cancer Cell Res 2008;18:538-548.